




## SUPPLEMENTAL MATERIAL

Batten et al., <http://www.jem.org/cgi/content/full/jem.20100064/DC1>


**Figure S1. Regulation of IL-21 by IL-27.** CD4<sup>+</sup> T cells from C57BL/6 mice were stimulated with plate-bound anti-CD3 and soluble anti-CD28 under TH0 polarizing conditions in the presence (filled symbols) or absence (open symbols) of rmIL-27 and in the presence or absence of cycloheximide for 5 h. The mean of triplicate experimental samples is given  $\pm$  SD. Data are representative of three independent experiments. (B) Naive CD4<sup>+</sup> T cells isolated from human PBMC were stimulated with T cell activation beads in the presence (filled bars) or absence (open bars) of rhIL-27 for 3 d. The expression of *IL12RB1* (left) and *IL-12RB2* (right) mRNA expression was measured by real-time RT-PCR and is given relative to human *gapdh*. Combined data from three independent donors and experiments is shown  $\pm$  SD. (C) CD4<sup>+</sup> T cells enriched from C57BL/6 splenocytes were stimulated with plate-bound anti-CD3 and soluble anti-CD28 in the presence of varying concentrations of rmIL-27, rmIL-12, or both rmIL-27 and rmIL-12 for 72 h. IL-21 in the culture supernatant was measured by ELISA and the mean  $\pm$  SD of triplicate experimental samples is shown. (D) CD4<sup>+</sup> T cells from STAT1<sup>+/+</sup> (SvEv) or STAT1<sup>-/-</sup> mice were stimulated as in A for 72 h. IL-21 in the culture supernatant was measured by ELISA. Data in D are representative of two experiments. n.t., no treatment; n.d., not detectable. \*,  $P < 0.05$  (unpaired Student's *t* test). Bars indicate mean  $\pm$  SEM.



**Figure S2. Detailed analysis of  $T_H$  cell reduction in *Il27ra*<sup>-/-</sup> mice.** (A) Groups of *Il27ra*<sup>+/+</sup> and *Il27ra*<sup>-/-</sup> mice were immunized twice with TNP-OVA in adjuvant and, 7 d after the second immunization, tissue was collected for analysis. Representative flow cytometric analysis for  $T_H$  marker expression in the spleen (left) and DLN (right). For all plots the CD4<sup>+</sup>B220<sup>-</sup> gate is shown. (B) The percentage of CXCR5<sup>+</sup>PD1<sup>+</sup> cells in the CD4<sup>+</sup>B220<sup>-</sup> gate in the spleen and DLN of unimmunized age-matched *Il27ra*<sup>+/+</sup> and *Il27ra*<sup>-/-</sup> mice. Data are representative of three independent experiments. (C) Groups of *Il27ra*<sup>+/+</sup> and *Il27ra*<sup>-/-</sup> mice were immunized once with TNP-OVA in CFA and FTY720 was administered i.p. every second day beginning on the day of immunization. Efficacy of the FTY720 treatment was confirmed by a >90% reduction in normal T cell number in the blood. 7 d after the immunization, tissue was collected for analysis. The percentage of CXCR5<sup>+</sup>PD1<sup>+</sup> cells in the CD4<sup>+</sup>B220<sup>-</sup> gate in the spleen and DLN is given. (D) Groups of *Il27ra*<sup>+/+</sup> and *Il27ra*<sup>-/-</sup> mice were immunized once with TNP-OVA in CFA. Where indicated, 20  $\mu$ g/mouse of IL-21R-Fc was administered i.v. every second day beginning 1 d before immunization. 7 d after immunization, tissue was collected for analysis. The percentage of CXCR5<sup>+</sup>PD1<sup>+</sup> cells in the CD4<sup>+</sup>B220<sup>-</sup> gate in the spleen and DLN is given. For C and D, a single experiment with seven animals per group is represented and error bars indicate SEM. \*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$  (unpaired Student's *t* test). Bars indicate mean  $\pm$  SEM.



**Figure S3. T cell-intrinsic defect in GC activity in *Il27ra*<sup>-/-</sup> mice (A–C)** TCM mice (CD45.1 and Thy1.1) were lethally irradiated and reconstituted with a 50:50% mix of BM from WT (CD45.1) and *Il27ra*<sup>-/-</sup> (CD45.2) mice (A and B). 6 wk after BM transfer, the mice were bled to assess reconstitution by flow cytometry. (A) The percentage of WT (filled circles), *Il27ra*<sup>-/-</sup> (open squares), and host (filled triangles) CD4<sup>+</sup> T cells in the mixed chimeras. (B) The percentage of WT (CD45.1<sup>+</sup> host plus donor; filled circles) and *Il27ra*<sup>-/-</sup> (open squares) in the B220<sup>+</sup> B cell gate in the mixed chimeras. (C) Serum IgG1 levels as determined by ELISA using TNP<sub>2</sub>-BSA coating in the mixed chimera (triangles) compared with chimeric mice reconstituted with only *Il27ra*<sup>-/-</sup> (squares) or *Il27ra*<sup>+/+</sup> (WT; circles) BM. (D–F) DO11.10Tg.*Il27ra*<sup>+/+</sup> (WT) or DO11.10Tg.*Il27ra*<sup>-/-</sup> (KO) CD4<sup>+</sup> T cells were adoptively transferred into either *Il27ra*<sup>+/+</sup> (WT) or *Il27ra*<sup>-/-</sup> (KO) hosts (as indicated) on the BALB/c background. The mice were immunized with OVA in CFA and the response analyzed 7 d later. Flow cytometric analysis was used to determine the percentage of CD4<sup>+</sup>KJ1<sup>+</sup> donor cells that became CXCR5<sup>+</sup>PD1<sup>+</sup> (D), KJ1<sup>+</sup> donor cells as a percentage of total CD4<sup>+</sup> cells (E), and the percentage of Fas<sup>+</sup>GL7<sup>+</sup> GC B cells in the spleen (F). Bars indicate the mean ± SEM. Each dataset is representative of two independent experiments. \*, P < 0.05; \*\*, P < 0.01 (unpaired Student's *t* test).



**Figure S4. IL-27 does not promote  $T_{FH}$  differentiation.** (A) OTII Tg  $CD4^+$  T cells were cultured with irradiated splenic APC plus  $0.3 \mu M$  OVA<sub>323-339</sub> peptide under TH0 conditions and in the presence of either no additional cytokine or various concentrations of rmlL-27 for 5 d. After 5 d,  $CD4^+$  T cells were restimulated with anti-CD3 for 4 h and IL-21, PD1, Bcl-6, and CXCR5 mRNA levels were assessed by real-time RT-PCR. mRNA levels for each probe set were normalized to the housekeeping gene Rpl19 and the fold increase relative to samples stimulated in the absence of rmlL-27 are given. The mean  $\pm$  SEM of triplicate experimental samples is shown and data are representative of two experiments. (B) Thy1.1<sup>+</sup> OTII TCR Tg  $CD4^+$  T cells were isolated by magnetic purification and cultured with irradiated splenic APC plus OVA<sub>323-339</sub> peptide under TH0 conditions alone (blocking antibodies against IFN- $\gamma$  and IL-4 and TGFBR11-Fc) or with the addition of 50 ng/ml rmlL-21 or 50 ng/ml rmlL-27 for 5 d. Cells were then adoptively transferred to naive Thy1.2 congenic hosts ( $n = 4-8$  per group) before recipient mice were subcutaneously immunized with 100  $\mu g$  OVA in IFA. Two additional control groups were included that did not receive cell transfers; one group was immunized as described, whereas the other group remained unimmunized. 7 d after immunization, differentiation of GC B cells in the LN were assessed by flow cytometry. The graph shows the mean percentage of GL7<sup>+</sup>Fas<sup>+</sup>B220<sup>+</sup> cells in the DLN. Error bars indicate SEM. (C) DO11.10tg.rag2<sup>-/-</sup> or DO11.10tg.rag2<sup>-/-</sup>.IL27ra<sup>-/-</sup> splenocytes were activated with various concentrations of OVA<sub>323-339</sub> in the presence or absence of 20 ng/ml rmlL-27 or 10  $\mu g$ /ml of anti-IL-27 for 72 h and the percentage of AnV-neg and 7AAD-neg (viable) cells in the  $CD4^+$  gate was determined by flow cytometry. Data are representative of three independent experiments. (D) OTII.IL21R<sup>+/+</sup> and OTII.IL21R<sup>-/-</sup> splenocytes were stimulated with OVA<sub>323-339</sub> peptide for 72 h in the absence of additional cytokine (open bars) or in the presence of rmlL-27 (black bars) or rmlL-21 (gray bars). 7AAD<sup>neg</sup>  $CD4^+$  cells were assessed by flow cytometry and multiplied by total cells counts to give viable  $CD4^+$  cells per ml of culture medium. The mean of three replicate samples are shown, and these data are representative of two independent experiments. Error bars indicate SEM. \*,  $P < 0.05$ , (unpaired Student's  $t$  test).

**Table S1.** Primers and probes for real-time RT-PCR

Gene	Primers	Probe
<i>mIi21</i>	5'-CTCCCGTGTCAAGGATT-3'; 5'-TCACAGTTGGGCAATAAGATG-3'	5'-AGCCACAGCTTGAGAAGCACCAGA-3'
<i>mIi27p28</i>	5'-TCAGGTGTCATCCAAGTGT-3'; 5'-GACAAGCTCCAGGGAGTGA-3'	5'-GGTAGGTATAGAGCAGCTGGGGCCAG-3'
<i>mEbi3</i>	5'-GGCCTGCTCTGAGTCTGAATA-3'; 5'-AGTCAAGTGAATTATCCAGTGCTT-3'	5'-CTTCCATGTACTGGGCTGCTCCG-3'
<i>mRpl19</i>	5'-ATCCGCAAGCCTGTGACTGT-3'; 5'-TCGGGCCAGGGTGTGTTT-3'	5'-TTCCCGGGCTCGTTGCCG-3'
<i>mBcl6</i>	Inventoried Taqman assay Mm00477633_m1	
<i>hGAPDH</i>	5'-CTCTGCTCCTCTGTTTCGAC-3'; 5'-ACGACCAAATCCGTTGACTC-3'	Roche UPL probe #60
<i>hIL12RB1</i>	5'-CGGCTGACCCTGAAAGAG-3'; 5'-CAGCCCTTGACAGCCTTC-3'	Roche UPL probe #78
<i>hIL12RB2</i>	5'-TCCAGATCCAGCAAATAGCA-3'; 5'-GTCCAAGGGCAGCTGTGT-3'	Roche UPL probe #82